Research Nester released a report titled “Chronic Kidney Disease Drugs Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global chronic kidney disease drugs market in terms of market segmentation by drugs and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

Chronic kidney disease (CKD) is a kidney disorder that eventually leads to permanent loss of function in kidneys if not treated on time. The disease can be treated with the aid of medications, dialysis and kidney transplantation. The market for chronic kidney disease drugs is estimated to grow at a CAGR of about 4.5% during the forecast period, i.e., 2019-2027. The market is segmented by drug and by region, out of which, the drug segment is further segmented into antihypertensive agents, erythropoiesis-stimulating agents (EPAs), diuretics and others. Based on these, the antihypertensive agents segment is predicted to observe the highest growth over the forecast period on account of a greater demand for these drugs. Antihypertensive agents are used for lowering the blood pressure, which is a symptom of chronic kidney disease, therefore, these drugs help to control these symptoms and treat the condition.

The market in North America is anticipated to hold the largest share in chronic kidney disease drugs market as a result of growing research and development activities and the presence of a large number of manufacturers in the industry. On the other hand, the market in Asia Pacific is estimated to grow at the highest rate during the forecast period on account of the increasing patient population with kidney disorders in the region and rising awareness about these renal disorders among them.

Growing Geriatric Population To Drive The Demand For CKD Drugs

The risk of chronic kidney disease increases significantly among the globally rising elderly population which results from disorders such as diabetes, cardiovascular disease, obesity and high blood pressure. The requirement for effective treatment methods and drugs accompanying them is anticipated to result in the growth of chronic kidney disease drugs market. However, the rising competition among various chronic kidney disease drugs available in the market is anticipated to become a major limiting factor for the market growth.

This report also provides the existing competitive scenario of some of the key players of the global chronic kidney disease drugs market which includes company profiling of AstraZeneca (LON: AZN), Amgen Inc. (NASDAQ: AMGN), Pfizer Inc. (NYSE: PFE), F. Hoffmann-La Roche (SWX: ROG), GlaxoSmithKline plc. (LON: GSK), FibroGen, Inc. (NASDAQ: FGEN), Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd. (TLV: TEVA), AbbVie Inc. (NYSE: ABBV) and Akebia Therapeutics, Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global chronic kidney disease drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.